The Porto European Cancer Research Summit 2021
(2021) In Molecular Oncology 15(10). p.2507-2543- Abstract
Key stakeholders from the cancer research continuum met in May 2021 at the European Cancer Research Summit in Porto to discuss priorities and specific action points required for the successful implementation of the European Cancer Mission and Europe's Beating Cancer Plan (EBCP). Speakers presented a unified view about the need to establish high-quality, networked infrastructures to decrease cancer incidence, increase the cure rate, improve patient's survival and quality of life, and deal with research and care inequalities across the European Union (EU). These infrastructures, featuring Comprehensive Cancer Centres (CCCs) as key components, will integrate care, prevention and research across the entire cancer continuum to support the... (More)
Key stakeholders from the cancer research continuum met in May 2021 at the European Cancer Research Summit in Porto to discuss priorities and specific action points required for the successful implementation of the European Cancer Mission and Europe's Beating Cancer Plan (EBCP). Speakers presented a unified view about the need to establish high-quality, networked infrastructures to decrease cancer incidence, increase the cure rate, improve patient's survival and quality of life, and deal with research and care inequalities across the European Union (EU). These infrastructures, featuring Comprehensive Cancer Centres (CCCs) as key components, will integrate care, prevention and research across the entire cancer continuum to support the development of personalized/precision cancer medicine in Europe. The three pillars of the recommended European infrastructures – namely translational research, clinical/prevention trials and outcomes research – were pondered at length. Speakers addressing the future needs of translational research focused on the prospects of multiomics assisted preclinical research, progress in Molecular and Digital Pathology, immunotherapy, liquid biopsy and science data. The clinical/prevention trial session presented the requirements for next-generation, multicentric trials entailing unified strategies for patient stratification, imaging, and biospecimen acquisition and storage. The third session highlighted the need for establishing outcomes research infrastructures to cover primary prevention, early detection, clinical effectiveness of innovations, health-related quality-of-life assessment, survivorship research and health economics. An important outcome of the Summit was the presentation of the Porto Declaration, which called for a collective and committed action throughout Europe to develop the cancer research infrastructures indispensable for fostering innovation and decreasing inequalities within and between member states. Moreover, the Summit guidelines will assist decision making in the context of a unique EU-wide cancer initiative that, if expertly implemented, will decrease the cancer death toll and improve the quality of life of those confronted with cancer, and this is carried out at an affordable cost.
(Less)
- author
- organization
- publishing date
- 2021-10
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Cancer Mission, cancer research/care/prevention continuum, clinical/prevention trials, comprehensive cancer centres, infrastructures for translational cancer research, outcomes research, science policy
- in
- Molecular Oncology
- volume
- 15
- issue
- 10
- pages
- 37 pages
- publisher
- Elsevier
- external identifiers
-
- pmid:34515408
- scopus:85114897969
- ISSN
- 1574-7891
- DOI
- 10.1002/1878-0261.13078
- language
- English
- LU publication?
- yes
- id
- 1f84a5e5-e299-4ddc-aa6b-4cb7388070cf
- date added to LUP
- 2021-10-11 14:46:56
- date last changed
- 2025-01-13 14:58:02
@article{1f84a5e5-e299-4ddc-aa6b-4cb7388070cf,
abstract = {{<p>Key stakeholders from the cancer research continuum met in May 2021 at the European Cancer Research Summit in Porto to discuss priorities and specific action points required for the successful implementation of the European Cancer Mission and Europe's Beating Cancer Plan (EBCP). Speakers presented a unified view about the need to establish high-quality, networked infrastructures to decrease cancer incidence, increase the cure rate, improve patient's survival and quality of life, and deal with research and care inequalities across the European Union (EU). These infrastructures, featuring Comprehensive Cancer Centres (CCCs) as key components, will integrate care, prevention and research across the entire cancer continuum to support the development of personalized/precision cancer medicine in Europe. The three pillars of the recommended European infrastructures – namely translational research, clinical/prevention trials and outcomes research – were pondered at length. Speakers addressing the future needs of translational research focused on the prospects of multiomics assisted preclinical research, progress in Molecular and Digital Pathology, immunotherapy, liquid biopsy and science data. The clinical/prevention trial session presented the requirements for next-generation, multicentric trials entailing unified strategies for patient stratification, imaging, and biospecimen acquisition and storage. The third session highlighted the need for establishing outcomes research infrastructures to cover primary prevention, early detection, clinical effectiveness of innovations, health-related quality-of-life assessment, survivorship research and health economics. An important outcome of the Summit was the presentation of the Porto Declaration, which called for a collective and committed action throughout Europe to develop the cancer research infrastructures indispensable for fostering innovation and decreasing inequalities within and between member states. Moreover, the Summit guidelines will assist decision making in the context of a unique EU-wide cancer initiative that, if expertly implemented, will decrease the cancer death toll and improve the quality of life of those confronted with cancer, and this is carried out at an affordable cost.</p>}},
author = {{Ringborg, Ulrik and Berns, Anton and Celis, Julio E. and Heitor, Manuel and Tabernero, Josep and Schüz, J. and Baumann, Michael and Henrique, Rui and Aapro, Matti and Basu, P. and Beets-Tan, Regina and Besse, Benjamin and Cardoso, Fátima and Carneiro, Fátima and van den Eede, G. and Eggermont, Alexander and Fröhling, Stefan and Galbraith, Susan and Garralda, E. and Hanahan, Douglas and Hofmarcher, Thomas and Jönsson, Bengt and Kallioniemi, Olli and Kásler, Miklós and Kondorosi, Eva and Korbel, Jan and Lacombe, Denis and Carlos Machado, José and Martin-Moreno, J. M. and Meunier, Francoise and Nagy, Péter and Nuciforo, Paolo and Oberst, S. and Oliveiera, Júlio and Papatriantafyllou, Maria and Ricciardi, Walter and Roediger, A. and Ryll, Bettina and Schilsky, Richard and Scocca, Grazia and Seruca, R. and Soares, Marta and Steindorf, Karen and Valentini, Vincenzo and Voest, Emile and Weiderpass, Elisabete and Wilking, Nils and Wren, Amanda and Zitvogel, Laurence}},
issn = {{1574-7891}},
keywords = {{Cancer Mission; cancer research/care/prevention continuum; clinical/prevention trials; comprehensive cancer centres; infrastructures for translational cancer research; outcomes research; science policy}},
language = {{eng}},
number = {{10}},
pages = {{2507--2543}},
publisher = {{Elsevier}},
series = {{Molecular Oncology}},
title = {{The Porto European Cancer Research Summit 2021}},
url = {{http://dx.doi.org/10.1002/1878-0261.13078}},
doi = {{10.1002/1878-0261.13078}},
volume = {{15}},
year = {{2021}},
}